CLL Research Affiliations
The Cancer and Leukemia Group B (CALGB) is a national clinical research group sponsored by the National Cancer Institute (NCI), with its central office headquartered at the University of Chicago and its statistical center located at Duke University. The CALGB was founded in 1955 with a goal of bringing together clinical oncologists and laboratory investigators to develop better treatments for cancer. Since then, CALGB has grown into a national network of 29 university medical centers, over 185 community hospitals and more than almost 3,000 physicians who collaborate in clinical research studies aimed at reducing the morbidity and mortality from cancer, relating the biological characteristics of cancer to clinical outcomes and developing new strategies for the early detection and prevention of cancer.
The Cancer Trials Support Unit (CTSU) is a pilot project sponsored by the NCI for the support of a national network of physicians to participate in NCI-sponsored Phase III cancer treatment trials. Its objectives are to increase physician and patient access to NCI-sponsored clinical trials, streamline and standardize trial data collection and reporting and reduce regulatory/administrative burden on investigators participating in NCI-sponsored cooperative group clinical trials (phases 1-3).
The CLL Research Consortium is a multi-institution research program sponsored by NCI to study chronic lymphocytic leukemia (CLL) in an entirely new way. The CLL Research Consortium has its national coordinating office at the University of California - San Diego, School of Medicine under the direction of Dr. Thomas Kipps. The consortium is unique in that it brings together the nation's top scientists from different disciplines; genetics, cell biology, biochemistry, immunology and pharmacology, to conduct an integrated program of basic and clinical research focused on a single disease.